Journals / Türk Üroloji Dergisi/Turkish Journal of Urology / 2013 / Cilt: 39 - Sayı: 3

How should prostate specific antigen be interpreted?

Prostat spesifik antijen nasıl yorumlanmalıdır?

Pages
188–193
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Initially, the upper limit for PSA was 4 ng/mL, but today, a reduction for the upper limit is recommended to 2.5-3 ng/mL for patients between 60 and 65 years and younger.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Since from its clinical introduction to the present time, measurement of serum Prostate Specific Antigen (PSA) level is one of the most widely used tests in urology practice.
📊
Key Findings & Data:Initially, the upper limit for PSA was 4 ng/mL, but today, a reduction for the upper limit is recommended to 2.5-3 ng/mL for patients between 60 and 65 years and younger.
💡
Conclusion & Impact:All in all, together with a good patient information, PSA test should be performed at appropriate intervals for appropriate people with an appropriate age.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Since from its clinical introduction to the present time, measurement of serum Prostate Specific Antigen (PSA) level is one of the most widely used tests in urology practice. Initially, the upper limit for PSA was 4 ng/mL, but today, a reduction for the upper limit is recommended to 2.5-3 ng/mL for patients between 60 and 65 years and younger. On the use of PSA as a screening test for prostate cancer, there are differences of opinion. However, it is a recommended test in the evaluation and monitoring of the risky group for prostate cancer. All in all, together with a good patient information, PSA test should be performed at appropriate intervals for appropriate people with an appropriate age.

Özet

Klinik kullanıma girmesinden günümüze kadar serum prostat spesifik antijen (PSA) düzeyinin ölçümü üroloji pratiğinde en yaygın kullanılan testlerden biridir. Başlangıçta PSA için üst sınır 4 ng/mL olarak önerilmesine rağmen günümüzde 60-65 yaş ve altındaki hastalar için üst sınırın 2,5-3 ng/mL düzeylerine kadar düşürülmesi önerilmektedir. Prostat kanseri için PSA’nın tarama testi olarak kullanımı konusunda görüş ayrılıkları vardır. Ancak prostat kanseri için riskli grubun değerlendirilmesi ve takibinde kullanılma- sı önerilen bir testtir. Sonuçta iyi bir hasta bilgilendirmesi ile beraber uygun kişilerde, uygun yaşta ve uygun aralıklarla PSA testi yapılmalıdır.

🔖

Cite This Article

ATAN, A., GÜZEL, Ö. (2013). How should prostate specific antigen be interpreted?. Türk Üroloji Dergisi/Turkish Journal of Urology, Cilt: 39 - Sayı: 3, 188–193. https://ajindex.com/articles/328012

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (3)

  1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979;17:159-63
  2. Venderbos LD, Roobol MJ. PSA-based prostate cancer screening: the role of active surveillance and informed and shared decision making. Asian J Androl 2011;13:219-24. [CrossRef] 3. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 1987;317:909-16. [CrossRef] 4. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-61. [CrossRef] 5. Woolf SH, Krist A. Shared decision making for prostate cancer screening: do patients or clinicians have a choice? Arch Intern Med 2009;169:1557-9. [CrossRef] 6. Myrtle J, Ivor L. Measurement of PSA in Serum by two immu- nometric Methods (Hybritech Tandem-R/Tandem-E PSA). In: Ca- talona WJ (ed), Clinical Aspects of Prostate Cancer. New York, Elsevier. 1989.pp.161-71
  3. Gjertson CK, Albertsen PC. Use and assessment of PSA in prostate cancer. Med Clin North Am 2011;95:191-200. [CrossRef] 8. Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, et al. Prostate specific antigen best practice statement: 2009 update. J Urol 2013;189:2-11. [CrossRef] 9. Atan A, Horn T, Hansen F, Jakobsen H, Hald T. Prostatic specific antigen and benign prostatic hyperplasia. Scand J Urol Nephrol 1996;30:299-302. [CrossRef] 10.Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Can- cer J Clin 2010;60:277-300. [CrossRef] 11. Mettlin C, Murphy GP, Lee F, Littrup PJ, Chesley A, Babaian R, et al. Characteristics of prostate cancers detected in a multimodality early detection program. The Investigators of the American Can- cer Society-National Prostate Cancer Detection Project. Cancer 1993;72:1701-8. [CrossRef] 12. Catalona WJ. Treatment strategies for prostate cancer. JAMA 1993;270:1691. [CrossRef] 13. Mottet N, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part II: Treatment of advan- ced, relapsing, and castration-resistant prostate cancer. Eur Urol 2011;59:572-83. [CrossRef] 14. van Renterghem K, Van Koeveringe G, Achten R, van Kerreb- roeck P. A new algorithm in patients with elevated and/or ri- sing prostate-specific antigen level, minor lower urinary tract symptoms, and negative multisite prostate biopsies. Int Urol Nephrol 20